Uploaded July 2026 | Updated September 2026, 2 weeks ago

---

Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), explains why validated biomarkers and surrogate endpoints could become the foundation for bringing longevity therapies into mainstream medicine. As the field matures, measuring whether interventions truly work may be just as important as discovering them, helping turn promising science into evidence-based care.

Full Episode on YouTube, Spotify and Apple Podcast. Link in the bio.

#LongevityTechnologyUnlocked #LongevityPodcast #Longevity #DylanLivingston #Biomarkers #Geroscience #ClinicalTrials #Healthspan